• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Discovering the Emerging Importance of PARG in Immunity

by Bellbrook Labs / Monday, 08 August 2022 / Published in Emerging Targets, HTS Assays, Innate Immunity
PARG in Human Immunity

Poly (ADP-ribose) glycohydrolase (PARG), along with poly (ADP-ribose) polymerase 1 (PARP1) are the principal elements of the DNA damage response (DDR). When single-strand breaks occur in cellular DNA, PARP1 mediates the poly ADP ribosylation of itself and target proteins, such as histones, promoting the decompaction of chromatin and recruiting relevant enzymes to initiate DNA repair. Poly (ADP-ribose) (PAR) carries a net charge that is twice as negative as DNA. Epigenetic PAR tagging literally forces chromatin open, making it accessible to repair enzymes and replication fork components.1

Eventually, PARP1 poly ADP ribosylates itself to the point of inactivity. Upon completion of the repair, PARG hydrolyzes poly (ADP-ribose) on PARP1 and similarly tagged associated proteins to diminish intracellular PAR and disassemble the repair machinery at a given site. This also reactivates the previously heavily poly ADP ribosylated PARP1. PARG is the only enzyme known to degrade PAR in the nucleus. Since Bruce Ames once reckoned that the average cell receives roughly 10,000 DNA damaging events each day, this system gets quite a workout.1

PARG’s Role in Immunity and Disease

While PARG was discovered about the same time as PARP1, much more research has been devoted to the influence of PARP1. PARG exists in lower cellular concentrations and is generally perceived as secondary to PARP1. However, recent research utilizing cells whose PARG levels can be precisely modulated, is revealing new insights.2

In mouse xenograft experiments, elevated levels of PARG reduced early tumorigenic potential without decreasing cell viability. A number of chemokine genes that encourage tumor growth are significantly downregulated by increased PARG levels. CCL2, known to drive tumor development at all stages, was reduced 3-fold. Reducing CCL2 impairs cancer stem cell renewal and the recruitment of monocytic myeloid-derived suppressor cells that blunt the anti-tumor immune response. CCL20, a factor that enhances cancer stemness, was downregulated 10-fold. CCL5, known to aid tumor cell invasion and migration by upregulating the production of extracellular matrix-degrading proteins, was downregulated 4-fold.3

High levels of PARG also induced upregulation of certain genes. ADGRG1, an adhesion molecule that is critical to the stability of vascular tissue, was upregulated 8-fold. Increased expression of ADGRG1 in melanoma effectively suppresses tumor angiogenesis. Curiously, SPON2 (spondin-2) was also upregulated by increased PARG levels. Spondin-2 is an excreted extracellular matrix protein that regulates innate immunity and enhances the anti-microbial response. While SPON-2 is found to be expressed in a variety of solid tumors, high expression promotes M1-like macrophage recruitment and inhibits metastasis.3

This very recent study is beginning to reveal the complex effects of PARG on cancer development, angiogenesis, and metastasis, in addition to its influence on innate and adaptive immunity.

References

1. James, D. I. et al. (2016) First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. ACS Chemical Biology, 11(11), 3179-3190. https://doi.org/10.1021/acschembio.6b00609
2. Dai, W. et al. (2019) Regulation of Wnt Singaling Pathway by Poly (ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Lung Cancer in Mice Induced by Benzo(a)pyrene Inhalation Exposure. Frontiers in Pharmacology, 10:338. https://doi.org/10.3389/fphar.2019.00338
3. Johnson, S. et al. (2022) PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment. BMC Cancer, 22:557. https://doi.org/10.1186/s12885-022-09651-9

Tagged under: Innate Immunity, PARG, Transcreener ADP Assay

What you can read next

Targeting Innate Immunity With NLRP3 Inhibitors
A Search for NLRP3 Inhibitors to Fight Autoimmune Disease
Validation of a GEF Inhibitor in Murine Models of Major Osteolytic Diseases
CDK12 Activity Assays Find Inhibitors Cancer Treatment
Finding Inhibitors for a Cancer Target: CDK12 Activity Assays Accelerate the Search

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP